CN103071150B - Chinese patent medicine for treating Alzheimer's disease - Google Patents
Chinese patent medicine for treating Alzheimer's disease Download PDFInfo
- Publication number
- CN103071150B CN103071150B CN201210531600.1A CN201210531600A CN103071150B CN 103071150 B CN103071150 B CN 103071150B CN 201210531600 A CN201210531600 A CN 201210531600A CN 103071150 B CN103071150 B CN 103071150B
- Authority
- CN
- China
- Prior art keywords
- disease
- alzheimer
- kidney
- blood
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 title claims abstract description 19
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 235000012054 meals Nutrition 0.000 claims abstract description 4
- 230000003203 everyday effect Effects 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 12
- 210000004369 blood Anatomy 0.000 abstract description 11
- 230000007812 deficiency Effects 0.000 abstract description 9
- 210000003734 kidney Anatomy 0.000 abstract description 9
- 230000017531 blood circulation Effects 0.000 abstract description 7
- 210000004556 brain Anatomy 0.000 abstract description 7
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 abstract description 6
- 235000001785 ferulic acid Nutrition 0.000 abstract description 6
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 abstract description 6
- 229940114124 ferulic acid Drugs 0.000 abstract description 6
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 abstract description 6
- 210000000952 spleen Anatomy 0.000 abstract description 6
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 abstract description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 5
- 208000026435 phlegm Diseases 0.000 abstract description 5
- 229930182490 saponin Natural products 0.000 abstract description 5
- 235000017709 saponins Nutrition 0.000 abstract description 5
- 150000007949 saponins Chemical class 0.000 abstract description 5
- 239000009636 Huang Qi Substances 0.000 abstract description 4
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 abstract description 4
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 abstract description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 abstract description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract description 4
- 235000008434 ginseng Nutrition 0.000 abstract description 4
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 abstract description 4
- 235000012661 lycopene Nutrition 0.000 abstract description 4
- 229960004999 lycopene Drugs 0.000 abstract description 4
- 239000001751 lycopene Substances 0.000 abstract description 4
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 abstract description 4
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 abstract description 3
- 229960004135 idebenone Drugs 0.000 abstract description 3
- 102000007625 Hirudins Human genes 0.000 abstract description 2
- 108010007267 Hirudins Proteins 0.000 abstract description 2
- 229930003779 Vitamin B12 Natural products 0.000 abstract description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 abstract description 2
- 229940006607 hirudin Drugs 0.000 abstract description 2
- 230000008506 pathogenesis Effects 0.000 abstract description 2
- 235000019163 vitamin B12 Nutrition 0.000 abstract description 2
- 239000011715 vitamin B12 Substances 0.000 abstract description 2
- 241000336291 Cistanche deserticola Species 0.000 abstract 1
- 244000124209 Crocus sativus Species 0.000 abstract 1
- 235000015655 Crocus sativus Nutrition 0.000 abstract 1
- 206010011469 Crying Diseases 0.000 abstract 1
- 241000893536 Epimedium Species 0.000 abstract 1
- 241000208343 Panax Species 0.000 abstract 1
- 235000002791 Panax Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- VZRKWGPIZJDNHC-UHFFFAOYSA-N Polygalic acid Natural products CC1(C)CCC2(CCC3=C(CCC4C5(C)CC(O)C(O)C(C)(C5CCC34C)C(O)=O)C2C1)C(O)=O VZRKWGPIZJDNHC-UHFFFAOYSA-N 0.000 abstract 1
- VZRKWGPIZJDNHC-LUNVCWBOSA-N Polygalic acid Polymers CC1(C)CC[C@@]2(CCC3=C(CC[C@@H]4[C@@]5(C)C[C@H](O)[C@H](O)[C@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2C1)C(O)=O VZRKWGPIZJDNHC-LUNVCWBOSA-N 0.000 abstract 1
- 241000037831 Polygonatum sibiricum Species 0.000 abstract 1
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 235000018905 epimedium Nutrition 0.000 abstract 1
- 231100000915 pathological change Toxicity 0.000 abstract 1
- 230000036285 pathological change Effects 0.000 abstract 1
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 14
- 241000005787 Cistanche Species 0.000 description 9
- 230000032683 aging Effects 0.000 description 7
- 239000003146 anticoagulant agent Substances 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 241000208340 Araliaceae Species 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- IRHTZOCLLONTOC-UHFFFAOYSA-N hexacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCO IRHTZOCLLONTOC-UHFFFAOYSA-N 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- SGAWOGXMMPSZPB-UHFFFAOYSA-N safranal Chemical compound CC1=C(C=O)C(C)(C)CC=C1 SGAWOGXMMPSZPB-UHFFFAOYSA-N 0.000 description 4
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 3
- WMHJCSAICLADIN-MVVLZTAMSA-N Picrocrocin Natural products O=CC=1C(C)(C)C[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)CC=1C WMHJCSAICLADIN-MVVLZTAMSA-N 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000013985 cinnamic acid Nutrition 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- -1 flavone compound Chemical class 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- 150000008131 glucosides Chemical class 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- WMHJCSAICLADIN-WYWSWGBSSA-N picrocrocin Chemical group C1C(C)=C(C=O)C(C)(C)C[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 WMHJCSAICLADIN-WYWSWGBSSA-N 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- ZZAJQOPSWWVMBI-UHFFFAOYSA-N calycosin Chemical compound C1=C(O)C(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZZAJQOPSWWVMBI-UHFFFAOYSA-N 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 208000013116 chronic cough Diseases 0.000 description 2
- 229930016911 cinnamic acid Natural products 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229930013686 lignan Natural products 0.000 description 2
- 235000009408 lignans Nutrition 0.000 description 2
- 150000005692 lignans Chemical class 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 235000017509 safranal Nutrition 0.000 description 2
- 229930193195 schizandrin Natural products 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- CPGCVOVWHCWVTP-LJAQVGFWSA-N (S)-nonacosan-10-ol Chemical compound CCCCCCCCCCCCCCCCCCC[C@@H](O)CCCCCCCCC CPGCVOVWHCWVTP-LJAQVGFWSA-N 0.000 description 1
- YZAZXIUFBCPZGB-QZOPMXJLSA-N (z)-octadec-9-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O YZAZXIUFBCPZGB-QZOPMXJLSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 102000005751 Alcohol Oxidoreductases Human genes 0.000 description 1
- 108010031132 Alcohol Oxidoreductases Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- SNMIMWYZCXBQQW-UHFFFAOYSA-N Bilobanol Natural products O1C(CC(C)C)=CC(C2CC(O)C(C)=CC2)=C1 SNMIMWYZCXBQQW-UHFFFAOYSA-N 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- SEBIKDIMAPSUBY-JAUCNNNOSA-N Crocin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C=CC=C(/C)C(=O)OC3OC(COC4OC(CO)C(O)C(O)C4O)C(O)C(O)C3O SEBIKDIMAPSUBY-JAUCNNNOSA-N 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 241000237903 Hirudo Species 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- POIRVLZGTSWEMG-UHFFFAOYSA-N Magnoflorin Natural products N1CCC2=CC(OC)=C(O)C3=C2C1CC1=CC=C(OC)C(O)=C13 POIRVLZGTSWEMG-UHFFFAOYSA-N 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- UOVGCLXUTLXAEC-IUODEOHRSA-N Methylnissolin Natural products O(C)c1c(OC)ccc2[C@@H]3[C@H](Oc12)c1c(OC3)cc(O)cc1 UOVGCLXUTLXAEC-IUODEOHRSA-N 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000308150 Orobanchaceae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000756042 Polygonatum Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041954 Starvation Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- KGGGRGBDMBZXKF-UHFFFAOYSA-N Virganreagenin G Natural products C1C(O)C(O)C(C)(CO)C2CCC3(C)C4(C)CC(O)C5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C KGGGRGBDMBZXKF-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- FDABVSXGAMFQQH-XZWHSSHBSA-N berbamunine Chemical compound CN1CCC2=CC(OC)=C(O)C=C2[C@H]1CC1=CC=C(O)C(OC2=CC=C(C=C2)C[C@@H]2N(C)CCC=3C=C(C(=CC=32)O)OC)=C1 FDABVSXGAMFQQH-XZWHSSHBSA-N 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- CPGCVOVWHCWVTP-UHFFFAOYSA-N celidoniol Natural products CCCCCCCCCCCCCCCCCCCC(O)CCCCCCCCC CPGCVOVWHCWVTP-UHFFFAOYSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 201000005667 central retinal vein occlusion Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- OXNHRKGZZFWUQZ-UHFFFAOYSA-N crocetin dimethyl ester Natural products COC(=O)C(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C(=O)OC OXNHRKGZZFWUQZ-UHFFFAOYSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- OXNHRKGZZFWUQZ-QORFUXSJSA-N gamma-Crocetin Chemical compound COC(=O)C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)OC OXNHRKGZZFWUQZ-QORFUXSJSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 201000003995 melancholia Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- RQFLGKYCYMMRMC-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O RQFLGKYCYMMRMC-UHFFFAOYSA-N 0.000 description 1
- IUCHKMAZAWJNBJ-RCYXVVTDSA-N oleanolic acid 3-O-beta-D-glucosiduronic acid Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O IUCHKMAZAWJNBJ-RCYXVVTDSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
According to the traditional Chinese medical science, spleen and kidney deficiency, dull expression, slow motion, immobility with few words all day, silly crying and giggling, eating and living inability, and empty brain are the basic pathological changes of the Alzheimer's disease, kidney essence deficiency is the basic pathogenesis, and phlegm coagulation and blood stasis promote the development of the Alzheimer's disease. The Chinese patent medicine treats the Alzheimer's disease through kidney tonifying, essence replenishing, phlegm reducing and blood circulation invigorating, and mainly comprises 30% of Manyprickle Acathopanax Root, 16% of Cistanche deserticola, 10% of Chinese magnoliavine, 8% of Polygonatum sibiricum, 8% of epimedium, 8% of Crocus sativus, 3% of salidroside, 3% of total saponins of panax notoginseseng, 2% of polygalic acid, 2% of lycopene, 2% of total saponins of ginseng, 2% of saponins of Radix Astragali, 2% of hirudin, 1.5% of idebenone, 1.5% of vitamin B12, and 1% of ferulic acid. The above sixteen medicines undergo ultrafine crushing according to proportions, and are uniformly stirred to prepare an electuary, and 2g of the electuary is continuously taken three times a day after meals for 9-12 weeks.
Description
One, technical field:
The invention belongs to medical technical field, relate to a kind of compound granules, refer to more specifically a kind of compound granules of preventing and treating alzheimer's disease.
Two, background technology:
Alzheimer's disease is common senile chronic disease, and current commercially available relevant medicine is poor effect all, or is difficult to fundamentally prevent and treat alzheimer's disease, and the present invention adopts Traditional Chinese medical theory monarch, the mutually auxiliary theoretical control alzheimer's disease of negative and positive.
Three, summary of the invention:
Alzheimer's disease is common senile chronic disease, differential diagnosis in tcm, and spleen deficiency of the kidney is damaged, witless expression, is slow in action, even keeping silence all day with no speaking, stupidly cry and laugh foolishly, daily life diet all needs people to look after, and brains inanition is that the basic pathology of alzheimer's disease changes, deficiency of kidney-essence is basic pathogenesis, the expectorant blood coagulation stasis of blood has promoted the development of alzheimer's disease, and the present invention controls from void opinion, kidney tonifying, essence replenishing, reduce phlegm and invigorate blood circulation as starting point treatment alzheimer's disease, main component and proportioning are as follows:
Radix Et Caulis Acanthopanacis Senticosi: another name Cortex Acanthopancis, thorn bent stick (Northeast China), Araliaceae Acanthopanax, the main component of Radix Et Caulis Acanthopanacis Senticosi is Radix Et Caulis Acanthopanacis Senticosi glucoside, the molecular formula C of Radix Et Caulis Acanthopanacis Senticosi glucoside
17h
24o
9, Radix Et Caulis Acanthopanacis Senticosi glucoside has blood vessel dilating, reduces blood pressure, anti-platelet aggregation, improve hemorheological characteristics and improve microcirculation; It can stimulate mind & body vigor, and it has antifatigue effect, strengthens endurance and ability, increases alertness and learning capacity; There is to excited and inhibition two-ways regulation in function of nervous system; There is calmness, suppress spontaneous activity, hypnosis, convulsion; Cure of depression, cerebral thrombosis.Replenishing QI to invigorate the spleen, tonifying the kidney for tranquilization; The Senile disease such as, inappetence weak for deficiency of spleen-YANG and kidneyYANG, body void, soreness of waist and knee joint, insomnia and dreamful sleep.This medicine is monarch drug of the present invention.
Herba Cistanches: another name Herba Cistanches, the fleshy stem of Orobanchaceae plant; Herba Cistanches is containing number of chemical composition, and Herba Cistanches contains the compositions such as abundant alkaloid, crystalline neutral substance, aminoacid, trace element, vitamin.Energy kidney-replenishing, benefiting essence-blood, can suppress the appearance of " yang deficiency " symptom, prevents from losing weight.Herba Cistanches is improving immunocompetence also.Herba Cistanches polysaccharides has significant impact to the formation of human lymphocyte and activity, and it can increase lymphocytic breeder reaction, thus the immunologic function of enhancing body.Herba Cistanches is scalable blood circulation also, has protection ischemic myocardium, blood fat reducing, and atherosclerosis, antithrombotic form; Reduce peripheral vascular resistance, expansion peripheral blood vessel, reduces blood pressure; The liver protecting, anti-fatty liver.The bright alcohol sugar of benzene contained in Herba Cistanches is the unexistent composition of other drug, and it is the most effective composition of slow down aging.Herba Cistanches all has obvious retarding action to the positions such as hypophysis cerebri, gonad, thymus under human body aging.
Fructus Schisandrae Chinensis: Magnoliaceae, Schizandra.< < herbal classic > >: main QI invigorating, cough with dyspnea, the thin degree of impairment caused by overstrain, tonifying for the deficiency, reinforcing YIN-essence.Main chemical compositions schizandrin (schizandrin).Fructus Schisandrae Chinensis contains abundant organic acid, vitamin, flavonoid, phytosterol and has the lignan of potent reactivation, it is also one of minority medical material having concurrently essence, gas, god's three large tonifications, the strong liver of energy QI invigorating, the efficiency of promoting cells exclude refuse, supply more oxygen, construction and uses energy, raising memory and property endurance.In ancient times, Russian hunter must take Fructus Schisandrae Chinensis to keep fit QI invigorating before going on a long journey at every turn and hunting.Fructus Schisandrae Chinensis can activate nervous system, promote respond, concentrate power and coordinative role, and it is clear to strengthen thinking.Although it has the effect of activation, there is no caffeine side effect restless.This slight berry, is also used to treat melancholia sometimes, and helps improvement agitation and forgetful problem.Strengthen device endurance research report and show, Fructus Schisandrae Chinensis is often used as the tonic of aging resistance and QI invigorating, and recent result of study has more been illustrated this principle.Research discovery, the contained lignan of Fructus Schisandrae Chinensis can strengthen the energy production of adenosine triphyosphate (ATP) or mitochondrion (cellular energy storehouse), and the line body of protection is simultaneously avoided oxidative pressure and is encroached on.Why these effects are enough to illustrate that Fructus Schisandrae Chinensis can slow down ageing process and delay to occur ageing-related disease, as heart failure, Alzheimer disease and Parkinson's disease.Above-mentioned two taste medicines are ministerial drug of the present invention.
Rhizoma Polygonati: have another name called Rhizoma Polygonati Cirrhifolii, Caput Gallus domesticus ginseng.Boosting qi and nourishing yin, spleen invigorating, lung moistening, kidney tonifying, Rhizoma Polygonati has blood pressure lowering, blood sugar lowering, blood fat reducing, atherosclerosis, slow down aging and the effect such as antibacterial, polygonatum polysaccharide has Immunestimulatory effect.For lung-dryness syndrome due to deficiency of YIN, the few expectorant of dry cough, and the chronic cough chronic cough of YIN-deficiency of the lung and kidney etc.For weakness of the spleen and stomach.Both tonifying spleen-yin, strengthening the spleen gas again, for deficiency of kidney essence, soreness of the waist and knees, has important auxiliary therapeutic action to alzheimer's disease.
Herba Epimedii: mainly containing flavone compound, lignanoid, alkaloid, volatilization wet goods. in the plants such as Herba Epimedii, contain ceryl alcohol (Ceryl alcohol), 1 alkane (Hentriacontane), plant sterol (Phytosterol), Palmic acid (Palmitic acid), stearic acid (Stearic acid), oleic acid (Oleic acid), linoleic acid (Linoleic acid), linolenic acid (Linolenic acid), ginnol (Bilobanol), magnoline (Magnoflorin), glucose (Glucose), fructose (Fructose), vitamin E etc.Can improve body's immunity; Can expand all blood vessels, improve microcirculation, increase blood flow, increase coronary flow; Have antitussive, eliminate the phlegm, anti-hypoxia, calmness, anticonvulsant action, for insufficiency of kidney-YANG, sexual impotence frequent micturition; Rheumatic arthralgia, numb limbs and tense tendons contracture, muscles and bones flaccidity is soft, walks with difficulty; Insufficiency of kidney-YANG, breathes with cough and loses heart.
Stigma Croci, main component is picrocrocin (C
16H
26O
7).Coloring material is crocin (C
44h6
4o
26H
2o).Chemical composition is containing crocin-1,2,3,4 (crocin-1~4), picrocrocin (picrocrocin), bayer acid dimethyl ester (crocetindimethyl ester), α-bayer acid (a-crocetin) safranal (safranal), volatilization wet goods.Have, immunoregulation effect, Stigma Croci is used for the treatment of the multiple chronic disease of human body clinically, by the effect of its blood circulation promoting and blood stasis dispelling, anti-inflammation, enhancing body endurance, strengthens lymphproliferation response, with this, improves Cellular Immunity and humoral immunization, play human functional activity of vital energy operation, the effect of balance yin-Yang adjusted.
Rhodioside: molecular formula C
14h
2oO
7there is enhancing immunity, eliminate melancholy sense, protection cardiovascular.
Radix Notoginseng total arasaponins: molecular formula C
47h8oO
17cure mainly blood circulation promoting and blood stasis dispelling, promote blood circulation active.There is the effect of anticoagulant and increase cerebral blood flow, for cerebrovascular sequelae, central retinal vein occlusion etc.Above-mentioned five kinds of Chinese medicine is adjuvant drug of the present invention.
Polygalacic acid: molecular formula C
3oH
48O6 has stronger phlegm-dispelling functions; The dead drunk enzyme of cyclic adenosine monophosphate di(2-ethylhexyl)phosphate is had to inhibitory action; Energy physical strength reinforcing and intelligence; There is stronger haemolysis, aldehyde ketone reductase is had to inhibitory action.In addition also have the effects such as mutation, anticancer, calm, convulsion, edema and diuresis.
Lycopene: its molecular formula is C
4oH
56 can prevent and suppress cancer, protection cardiovascular, and slow down aging, enhancing immunity: lycopene can be removed the free radical in human body most effectively, keep cell homergy, anti-aging in advance.Lycopene is absorbed and is entered blood and lymph by gastrointestinal mucosal in vivo, be distributed to testis, adrenal gland, prostate, pancreas, breast, ovary, liver, lung, colon, skin and various mucosal tissue, promote glandular secretion hormone, thereby make human body keep vigorous energy; Remove the free radical in these Organ and tissues, protect them to escape injury, enhancing human body immunity power.
Radix Ginseng total glycosides: Araliaceae, the extract of Radix Ginseng, be rich in 18 kinds of Saponins, can obviously suppress cylinder super-oxidation lipid and form, increase the content of Superoxide dismutase and peroxidase simultaneously, there is antioxidation, reduce interior free yl content, increase human body cell vigor, suppress old and feeble, reduce blood glucose.
Radix Astragali saponin: leguminous plant, the extract of the root of the Radix Astragali, containing flavones ingredient, calycosin, 3-hydroxy-9,10-dimethoxy pterocarpane, Radix Astragali saponin I, V, III, energy tonifying Qi and lifting yang, benefit is defended consolidating superficial resistance, regulates human body metabolism, and enhancing immunity improves antioxidant ability of organism.
Hirudin: be mainly that separating-purifying out, has anticoagulant from the saliva of Hirudo, the peptide material of antithrombotic effect, the clinical treatment that is usually used in multiple thrombotic disease, can eliminate angiemphraxis, makes hemocyte depolymerization, thrombosis dissipates, and promotes blood capillary logical again, improves microcirculating state.At present, be usually used in regulating blood fat, eliminate fatty liver, directly dissolve thrombosis, eliminate atherosclerosis, prevent apoplexy and apoplexy again, the thrombolytic function of human activin self, avoids again producing thrombolytic etc., to treating alzheimer's disease, also has effect.
Idebenone: molecular formula C
19h
3oO
5this medicine is that brain metabolism, mental symptom are improved medicine, can activate brain mitochondria respiratory activity, improves the brain energy metabolism of cerebral ischemia, improves glucose utilization rate in brain, makes ATP in brain produce increase.Idebenone is that the specific drug of novel anti-alzheimer's disease and brain function metabolism and mental symptom are improved medicine.The patients such as clinical, emotionally disturbed low for disordered brain function, consciousness, aphasis, dementia.
Ferulic acid: the chemical name of ferulic acid (Ferulic Acid) is 4 hydroxyl 3 methoxy cinnamic acids is one of derivants of cinnamic acid (claiming again cinnamic acid, 3 phenyl 2 acrylic acid).Ferulic acid has sedation, and ferulic acid has spasmolytic effect to smooth muscle, can increase cerebral blood flow.
Vitamin B12: molecular formula C6
3h88CoN
14o
14p eliminates dysphoria, focuses one's attention on, and hypermnesis and equilibrium sense are that nervous function perfects indispensable vitamin, participates in the formation of a kind of lipoprotein in nervous tissue, safeguards metabolism and the function of neural myelin.B is deficient in vitamin
12time, neurological disorder, spinal cord degeneration can be caused, and serious mental symptom can be caused.Vitamin B
12shortage can cause peripheral neuritis.B is deficient in vitamin
12early manifestation be mood disorders, have a dull expression on one's face, bradykinesia.
Vitamin B in old people colony
12the phenomenon of level deficiency is very general, should note supplementing in time, otherwise can reduce cognitive competence, accelerates the development of senile dementia.
Above-mentioned 16 kinds of medicines, by proportioning superfine grinding, uniform stirring is made electuary, each serving with 2 grams, every day three times, uses after meal warm boiled water, serve on 9~12 weeks.
Four, the specific embodiment:
The present invention uses more than 20 routine alzheimer's diseases, and each oral 2 grams of early stage patient, every day three times, serve on 9~12 weeks with warm boiled water after meal, and hands limb chatter symptom takes a turn for the better, and linguistic competence strengthens, and memory is recovered, and quality of life obviously improves.
Claims (1)
1. treat a Chinese patent medicine for alzheimer's disease, the one-tenth that it is characterized in that it be grouped into and proportioning as follows:
Above-mentioned 16 kinds of medicines, by proportioning superfine grinding, uniform stirring is made electuary, each serving with 2 grams, every day three times, uses after meal warm boiled water, serve on 9~12 weeks.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210531600.1A CN103071150B (en) | 2012-12-11 | 2012-12-11 | Chinese patent medicine for treating Alzheimer's disease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210531600.1A CN103071150B (en) | 2012-12-11 | 2012-12-11 | Chinese patent medicine for treating Alzheimer's disease |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103071150A CN103071150A (en) | 2013-05-01 |
CN103071150B true CN103071150B (en) | 2014-08-06 |
Family
ID=48147993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210531600.1A Expired - Fee Related CN103071150B (en) | 2012-12-11 | 2012-12-11 | Chinese patent medicine for treating Alzheimer's disease |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103071150B (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1745789A (en) * | 2004-09-08 | 2006-03-15 | 黄树民 | Head invigorating capsule and its preparation thereof |
CN101229293A (en) * | 2008-01-14 | 2008-07-30 | 北京中科雍和医药技术有限公司 | Medicine compounds for treating senile dementia and preparing method thereof |
WO2010110755A1 (en) * | 2009-03-27 | 2010-09-30 | Moleac Pte. Ltd. | Therapy for promoting cell growth |
CN102188471A (en) * | 2011-04-20 | 2011-09-21 | 长春中医药大学 | Pharmaceutical composition for treating Alzheimer disease symptom and its preparation method |
CN102772469A (en) * | 2011-05-11 | 2012-11-14 | 成都康弘药业集团股份有限公司 | Medicine composition used for preventing or treating senile dementia |
-
2012
- 2012-12-11 CN CN201210531600.1A patent/CN103071150B/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1745789A (en) * | 2004-09-08 | 2006-03-15 | 黄树民 | Head invigorating capsule and its preparation thereof |
CN101229293A (en) * | 2008-01-14 | 2008-07-30 | 北京中科雍和医药技术有限公司 | Medicine compounds for treating senile dementia and preparing method thereof |
WO2010110755A1 (en) * | 2009-03-27 | 2010-09-30 | Moleac Pte. Ltd. | Therapy for promoting cell growth |
CN102188471A (en) * | 2011-04-20 | 2011-09-21 | 长春中医药大学 | Pharmaceutical composition for treating Alzheimer disease symptom and its preparation method |
CN102772469A (en) * | 2011-05-11 | 2012-11-14 | 成都康弘药业集团股份有限公司 | Medicine composition used for preventing or treating senile dementia |
Non-Patent Citations (2)
Title |
---|
中药复方治疗老年痴呆的用药规律分析;胡增峣等;《中药药理与临床》;20121015;第28卷(第5期);第254-245页表3-4,第254页右栏最后1段 * |
胡增峣等.中药复方治疗老年痴呆的用药规律分析.《中药药理与临床》.2012,第28卷(第5期),第254-245页表3-4,第254页右栏最后1段. |
Also Published As
Publication number | Publication date |
---|---|
CN103071150A (en) | 2013-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103877263B (en) | A kind of antifatigue health preparation of the compound Chinese medicine such as red ginseng, maca, green-tea extract (theanine) | |
CN103263608B (en) | Chinese medicinal raw powder for detoxifying and beautifying | |
CN104799146A (en) | Functional nutritional good composition for improving sub-health and preparation method thereof | |
CN1170588A (en) | Pure natural plant human life energy nutritive substrate | |
CN102845745A (en) | Dendrobium officinale health-care product | |
CN102172385B (en) | A kind of Chinese medicine preparation with enhancing immunity, blood sugar lowering and effect for reducing blood fat | |
CN1846764A (en) | Health medicinal wine | |
CN103859378A (en) | Formula and preparation method of life cultivation and health preservation food helpful for reducing blood sugar | |
CN104146261A (en) | Traditional Chinese medicine health-care product for climacterium of women and preparation method thereof | |
CN104825801A (en) | TCM (traditional Chinese medicine) preparation for preventing and treating cardiovascular and cerebrovascular diseases | |
CN106562428A (en) | Facial beautification and body shaping soft extract and preparation method thereof | |
CN102727761B (en) | Medicine for treating alopecia seborrheica and preventing hair drying and bifurcating and method for preparing medicine | |
CN103157036A (en) | Health care traditional Chinese medicine having effects of skin care and breast enlargement | |
CN106937741A (en) | A kind of degreasing linseed meal cancer-resisting health slimming method and preparation method thereof | |
CN103463625B (en) | Nourish heart nutritional preparation of enriching blood | |
CN103142848B (en) | Anti-aging Chinese medicine preparation and preparation method thereof | |
CN103520302A (en) | Sea-buckthorn leaf anti-fatigue capsule and preparation method thereof | |
CN101284096A (en) | Sheep placenta capsule compound nest-defence capsule for beautifying face | |
CN103463409A (en) | Traditional Chinese medicine formula for treating heart qi deficiency | |
CN103071150B (en) | Chinese patent medicine for treating Alzheimer's disease | |
CN108633997A (en) | A kind of healthcare goat milk powder and preparation method thereof with anti-fatigue effect | |
CN104223306B (en) | Broad-spectrum high efficacy kidney tonifying is treating stranguria inflammation-diminishing function food and preparation method thereof | |
CN102861236A (en) | Anti-tumor preparation made of pure traditional Chinese medicines | |
CN102973687B (en) | Oral liquid for regulating female hormonal balance | |
CN102326655A (en) | Green healthcare longevity fruit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160805 Address after: 201100, room 160, seven village, 102 Yang Luo village, Shanghai, Minhang District Patentee after: Gao Yuzhen Address before: 201200 Shanghai city Pudong New Area Chuansha 54 paper Stone Road Lane 4, Room 502 Patentee before: Shanghai Pudong Gaoxing Biotechnology Research Institute |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140806 Termination date: 20171211 |
|
CF01 | Termination of patent right due to non-payment of annual fee |